ArticleNature communications2017
Absence of Grail promotes CD8
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Ubiquitin-centered post-translational modification crosstalk orchestrates tumor immunity and immunotherapy response.Experimental hematology & oncology · 2026Review
- E3 ubiquitin ligase RNF128 attenuates colitis and colorectal tumorigenesis by triggering the degradation of IL-6 receptors.Journal of advanced research · 2025Article
- RNF128 deficiency in macrophages promotes colonic inflammation by suppressing the autophagic degradation of S100A8.Cell death & disease · 2025Article
- CD28 co-stimulation: novel insights and applications in cancer immunotherapy.Nature reviews. Immunology · 2024Review
- ISG15/GRAIL1/CD3 axis influences survival of patients with esophageal adenocarcinoma.JCI insight · 2024Article
- E3 ubiquitin ligase RNF128 negatively regulates the IL-3/STAT5 signaling pathway by facilitating K27-linked polyubiquitination of IL-3Rα.Cell communication and signaling : CCS · 2024Article
- Mechanism of tumor-derived extracellular vesicles in prostatic cancer progression through the circFMN2/KLF2/RNF128 axis.Apoptosis : an international journal on programmed cell death · 2023Article
- RNF128 expression in lung adenocarcinoma is a favorable prognostic factor associated with decreased tumor-associated macrophages.Thoracic cancer · 2023Article
- Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets.Journal for immunotherapy of cancer · 2023Review
- Article
- ZAP70, too little, too much can lead to autoimmunity.Immunological reviews · 2022Review
- The roles of E3 ligases in Hepatocellular carcinoma.American journal of cancer research · 2022Review
- Cbl-b deficiency prevents functional but not phenotypic T cell anergy.The Journal of experimental medicine · 2021Article
- Targeting ubiquitin signaling for cancer immunotherapy.Signal transduction and targeted therapy · 2021Review
- RNF128 suppresses the malignancy of colorectal cancer cells via inhibition of Wnt/β-catenin signaling.American journal of translational research · 2021Article
- E3 Ubiquitin Ligases as Immunotherapeutic Target in Atherosclerotic Cardiovascular Disease.Frontiers in cardiovascular medicine · 2020Review
- Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment.Frontiers in oncology · 2020Review
- RNF128 Promotes Malignant Behaviors via EGFR/MEK/ERK Pathway in Hepatocellular Carcinoma.OncoTargets and therapy · 2020Article
- Beyond the Cell Surface: Targeting Intracellular Negative Regulators to Enhance T cell Anti-Tumor Activity.International journal of molecular sciences · 2019Review
- Ubiquitin Ligases in Cancer Immunotherapy - Balancing Antitumor and Autoimmunity.Trends in molecular medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 3 institutions in 2 countries.
Cara HaymakerDepartment of Melanoma Medical Oncology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0002-1317-9287
Yi YangDepartment of Immunology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
Junmei WangDepartment of Immunology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
Qiang ZouDepartment of Immunology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
Anupama SahooDepartment of Immunology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
Andrei AlekseevDepartment of Immunology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
Divyendu SinghDepartment of Immunology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
Krit RitthipichaiDepartment of Melanoma Medical Oncology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
Yared HailemichaelDepartment of Melanoma Medical Oncology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
Oanh N HoangDepartment of Immunology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
Hong QinDepartment of Lymphoma/Myeloma, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
Kimberly S SchlunsDepartment of Immunology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
Tiejun WangDepartment of Radiation Oncology, The Second Hospital of Jilin University, No. 218 Ziqiang St., Changchun City, Jilin Province, 130041, China.
Willem W OverwijkDepartment of Melanoma Medical Oncology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
Shao-Cong SunDepartment of Immunology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
Chantale BernatchezDepartment of Melanoma Medical Oncology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
Larry W KwakDepartment of Lymphoma/Myeloma, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
Sattva S NeelapuDepartment of Lymphoma/Myeloma, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
Roza NurievaDepartment of Immunology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA. rnurieva@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USCity Of Hope National Medical Center · USSecond Affiliated Hospital of Jilin University · CN
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MSignaling Functions of the Tumor Suppressor CYLDR01AI064639 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SUN, SHAO-CONG · 2006 to 2014
$3.6MRegulation of T-cell function and autoimmune inflammation by deubiquitinases.R37AI064639 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SUN, SHAO-CONG · 2015 to 2021
$2.8MRegulation of T cell activation and tolerance by GrailR01AI083761 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI NURIEVA, ROZA INSAFETDINOVNA · 2009 to 2013
$1.9MPredictors of clinical outcome after therapeutic vaccination in follicular lymphoR01CA155143 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAVIS, RICHARD ERIC, NEELAPU, SATTVA S · 2011 to 2014
$1.7MBiomarkers and Resistance Mechanisms in Melanoma T-cell TherapyR01CA184845 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HWU, PATRICK, MULE, JAMES J. · 2014 to 2018
$1.7MUT M.D. Anderson Cancer Center Lymphoma SPOREP50CA136411 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KWAK, LARRY W · 2009 to 2011
$1.5MFunctional Attributes of a CD8+BTLA+ T cell subset in Adoptive T Cell TherapyR21CA178580 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BERNATCHEZ, CHANTALE · 2013 to 2014
$377kRole of Grail in maintaining humoral immune toleranceR03AI120027 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI NURIEVA, ROZA INSAFETDINOVNA · 2015 to 2016
$160kNCI NIH HHS P30 CA016672NCI NIH HHS P50 CA136411NCI NIH HHS R01 CA155143NCI NIH HHS R01 CA184845NCI NIH HHS R21 CA178580NIAID NIH HHS R01 AI064639NIAID NIH HHS R01 AI083761NIAID NIH HHS R03 AI120027NIAID NIH HHS R37 AI064639
Abstract
T-cell tolerance is a major obstacle to successful cancer immunotherapy; thus, developing strategies to break immune tolerance is a high priority. Here we show that expression of the E3 ubiquitin ligase Grail is upregulated in CD8
Indexed as
AnimalsCD8-Positive T-LymphocytesHumansImmune ToleranceInterleukin-21InterleukinsLymphomaMiceMice, KnockoutNeutrophil InfiltrationReceptors, Interleukin-21Ubiquitin-Protein LigasesInterleukin-21InterleukinsReceptors, Interleukin-21RNF128 protein, mouseUbiquitin-Protein Ligases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.